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Abstract
Background: While obesity and fat intake have been associated with an increased risk of prostate cancer (PCa)
aggressiveness and mortality, the association between lipid levels and PCa phenotype remains unclear. Previous
reports evaluating this association are inconsistent and highly variable when considering different racial/ethnic
groups. There are scarce data regarding this association among Hispanics, and specifically Puerto Rico’s Hispanic
men, a population with a higher burden of PCa, metabolic syndrome and overweight. This population has a
different ancestry profile than other Hispanics from Central and South America. Due to the above the researchers
inquired if there is a relationship between serum lipid levels and PCa phenotype in this understudied population
using a cohort of patients treated with radical prostatectomy as their first treatment.
Methods: We performed an exploratory retrospective medical record review study of 199 PCa patients who
underwent radical prostatectomy between 2005 and 2012. Variables analyzed included age at PCa diagnosis, Body
Mass Index (BMI), preoperative serum prostate-specific antigen (PSA), lipid levels, and clinical parameters such as
prostatectomy pathologic stage and Gleason Score (GS). PCa severity was defined using pathologic stage and GS.
Unadjusted and adjusted logistic regression models were fitted to estimate the odds ratios (ORs) with 95 %
confidence intervals (CI) to define the relationship among clinical characteristics and PCa severity.
Results: Mean age for the cohort was 58.8 years (range: 40–75), 78.9 % were overweight or obese, 36.7 % had
hypertriglyceridemia, and 35.2 % had low HDL levels. In the unadjusted logistic regression model,
hypertriglyceridemia (OR: 2.11, 95 % CI = 1.13–3.93), low HDL (OR: 1.90, 95 % CI = 1.02–3.56-), and age (OR: 2.34,
95 % CI 1.25–4.40) were significantly associated with a diagnosis of high severity of PCa.
Conclusions: In Puerto Rican men with PCa, elevated hypertriglyceridemia, low HDL levels, and age were
statistically associated with high grade PCa on bivariate analysis. Total cholesterol level was not associated with
severity of disease. Associations lost significance upon multivariate adjustment. These data generate important
hypotheses regarding the potential relationship between lipid pathways and PCa development and underscore the
need to perform larger scale and longitudinal studies to sort out whether, hypertriglyceridemia is associated with
PCa phenotype and development.
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Background
In Puerto Rico, the age-adjusted incidence rate of pros-
tate cancer (PCa) between 2008 and 2012 was 152.8 per
100,000 men, while the age-adjusted death rate for the
same period was 30.6 per 100,000 men [1]. Of the 78
municipalities in the Island, 30 had an age-adjusted
death rate of 35 or higher, which highlights a possible
health disparity. Also for this period, prostate cancer
was the leading cause of death by cancer in men ac-
counting for 17.6 % of all cancer deaths in men. These
statistics show that PCa mortality in Puerto Rican men
is higher than in Caucasians and continental United
States (US) Hispanics [2–5], and warrants a study to
identify the underlying causes of this high death rate.
Previous data have shown that risk factors associated
with the development of PCa include age and family his-
tory. In addition a high dietary intake of animal fat or
meat, and obesity seems to be related to an increase in
the risk of developing the disease or its aggressiveness
[6, 7]. While studies evaluating the association between
obesity and PCa have been conflicting, most suggest that
obesity has a positive correlation with a higher risk of
developing high-grade PCa [8] and dying of PCa [9]. In
obese men, abdominal adiposity may be related to pro-
gression of existing disease and biochemical recurrence
after treatment [10].
In Puerto Rico, according to statistics of the Behavioral
Risk Factor Surveillance System (BRFSS) for 2012, 37.8 %
of citizens were overweight and 28.4 % were obese [11].
The BRFSS also indicates that 39 % of the population had
high cholesterol levels. Moreover, a cross-sectional study
evaluating the prevalence of metabolic syndrome in the
metropolitan area of San Juan Puerto Rico, established
that the prevalence of metabolic syndrome correlated with
increasing age, rising to 58.2 % in participants between the
ages of 70 and 80. Moreover, the researchers found that in
their study cohort, men had higher levels in triglycerides
than women [12].
Previous work by our group in 2010, established that
Puerto Rican Hispanic men with a higher BMI had a
higher prevalence of metastatic disease than those with a
low BMI. In addition, we also reported that obese or
overweight men with low levels of PSA had positive
prostate biopsies, making this a population at risk for
delayed diagnosis [13].
Other studies have established that cholesterol, triglyc-
erides, and lipoproteins may play a key role in prostate
oncogenesis and severity. Moses et al. in 2009 reported
that increased LDL serum levels were associated with a
higher risk of prostate cancer in African American men
but not in non-African American males [14]. However,
Adedapo and collaborators in 2012, reported that lower
serum levels of triglycerides and total cholesterol were
associated with benign prostate hyperplasia and prostate
cancer [15]. In that same year, Hayashi et al. found that
high triglycerides serum levels were positively correlated
to prostate cancer incidence in a sample of Japanese
men age 60 years or older. In addition, they also re-
ported that more aggressive prostate cancer cases de-
fined as having a GS of 8 or greater were significantly
associated with triglycerides levels above 150 mg/dL
[16]. In 2009, Platz, E. et al.[17] followed 5,586 men in
the placebo arm of the Prostate Cancer Prevention Trial
(PCPT), and reported that in a group of men with GS
8–10, those with low serum cholesterol levels had a
lower risk of high grade prostate cancer with worse
prognosis. Work by Solomon et al. in 2008 [18] suggests
an influence of cholesterol levels on the survival of can-
cer cells. Moreover the relationships between cholesterol
levels and high grade prostate cancer seem to be
dependent on BMI, with heavy men with low circulating
cholesterol showing lesser rates of high grade and ad-
vanced disease [19]. Although the above mentioned re-
search have brought light into the possible relationship
of lipids and the aetiology and phenotype of prostate
cancer, there has been limited participation of Hispanics
in general and Puerto Ricans in particular as part of the
studied cohorts.
Considering the high prevalence of metabolic syn-
drome in Puerto Rico, the BMI statistics, and the health
disparity in prostate cancer mortality rates in this popu-
lation, it is possible that lipid levels could influence the
prostate cancer phenotype in this population. We found
no evidence of a previous study associating serum lipid
levels with the characteristics of prostate cancer in a
Hispanic Puerto Rican population. Thus, in this explora-
tory study we tested the hypothesis that high triglycer-
ides and low HDL levels were associated with a more
severe cancer phenotype. This work contributes data
that must be considered in the clinical management of
PCa patients in a population of Hispanics, with a differ-
ent ancestry background than other Hispanic and racial/
ethnic groups [20].
Results
Mean age for the cohort was 58.8 years (range: 40 to
75). Overall, 99 participants (49.8 %) were ≥ 60 years old,
157 (78.9 %) were overweight or obese, 73(36.7 %) had
hypertriglyceridemia and 70 (35.2 %) had low HDL levels
(Table 1). Low severity PCa [GS (3 + 4 or less) with a
low pathologic stage (≤pT2c)] was found in 140 (70.4 %)
patients, while 59 (29.6 %) had high severity PCa.
Table 2 describes the demographic and clinical charac-
teristics in patients by PCa severity. PCa severity varied
significantly by age at cancer diagnosis, triglycerides, and
HDL cholesterol levels (p < 0.10). In the low severity
group, 97 (69.3 %) subjects had desirable HDL levels
(≥40 mg/dL) compared with 43 (30.7 %) with low HDL
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levels (p = 0.042). Low triglycerides levels were present
in 96 (68.46 %) of the subjects in the low severity group
and in 29 (50.9 %) of the subjects in the high severity
group (p = 0.018). We found a higher percentage (34 %)
of high severity PCA in patients with high triglycerides
and BMI < 30, and only in 20 % of patients with low tri-
glycerides levels in the same BMI group. Table 3 shows
the estimation of the unadjusted and adjusted OR (95 %
CI) and PCa severity. In the unadjusted regression
model, a higher BMI, age ≥ 60 years, high triglyceride
levels and low HDL were significantly associated with
PCa severity (p ≤ 0.10).
Discussion
PCa is a complex disease with phenotypes that appear to
arise as a result of “individualized” processes in each pa-
tient. Its development may be influenced by the personal
lifestyle and nutritional habits of each individual [21].
Obesity and hyperlipidemia among other components of
the metabolic syndrome are known risk factors for pros-
tate cancer [22, 23]. The Puerto Rican population has
unique characteristics in terms of nutritional habits and
lifestyle. Ho and colleagues showed that the traditional
diet of Puerto Ricans includes a low diversity of fruits and
vegetables consumption and is, therefore, “unhealthful”
[24]. Colon-Lopez, V. and collaborators in 2013 [25],
found that in a group of 593 Puerto Ricans living in the is-
land, only 19.5 % followed the recommendations for daily
exercise activity and only 4.2 % met both the daily exercise
and daily fruit and vegetables intake recommendations.
Moreover 40.4 % of the respondents reported they did not
believe exercise could lower their risk of cancer.
Abdominal obesity, hypertriglyceridemia, and low HDL
levels have a high prevalence among the population living
on the island [26]. Puerto Rican adult males are more
likely to be overweight regardless of age as reported by
Perez et al. [27]. Considering these phenotypes, and previ-
ous associations of lipid levels and PCa done by others in
non-Hispanic populations, [28, 29] we aimed to establish
if there was relationship between serum lipids levels and
prostate cancer grade in Puerto Rican men. We found that
high triglycerides and low HDL levels correlate each on its
own with high severity prostate cancer. Associations lost
significance upon multivariate adjustments.
BMI and PCa severity
When we analyzed the association of presurgical BMI
and PCa severity, our data suggest that in Puerto Rican
overweight and obese men there was an increased risk
for more severe disease. Nevertheless, the tendency is
Table 1 Demographics and clinical characteristics of study
sample (n = 199)
Characteristic n (%)
Age at PCA diagnosis (years)
<60 100 (50.25)
≥60 99 (49.75)

















Table 2 Description of demographic and clinical characteristics
by severity status of PCa
Characteristic PCa Severity p-value*
Low (n= 140) High (n= 59)
n (%) n (%)
Age at PCA diagnosis (years) 0.007
<60 79 (56.43) 21 (35.59)
≥60 61 (43.57) 38 (64.41)
BMI (Kg/m2) 0.216
<25.00 33 (23.57) 9 (15.25)
25–29.99 70 (50.00) 28 (47.46)
≥30.00 37 (26.43) 22 (37.29)
Cholesterol (mg/dL) 0.508
<200 90 (64.29) 35 (59.32)
≥200 50(35.71) 24 (40.68)
Triglycerides (mg/dL) 0.018
<150 96 (68.57) 30 (50.85)
≥150 44 (31.43) 29 (49.15)
HDL Cholesterol (mg/dL) 0.042
≥40 97 (69.29) 32 (54.24)
<40 43 (30.71) 27 (45.76)
LDL Cholesterol (mg/dL) 0.465
<160 126 (90.00) 51 (86.44)
≥160 14 (10.00) 8 (13.56)
*p-value from Pearson Chi-square test. Figures in bold have statistical significance
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marginally significant. These results must be interpreted
with caution considering the limitations imposed by
using BMI as an overweight/obesity measurement. Des-
pite its common use, BMI is not an exact measurement
of body fat and does not consider body fat mass and its
distribution. Therefore, it may misrepresent people with
high lean body mass [30, 31]. In addition, a limitation of
our study is that we do not have a longitudinal history
of the patients’ BMI, which hinders our ability to estab-
lish a direct relationship between high BMI and the on-
set and development of prostate cancer severity.
Triglycerides and PCa severity
When we analyzed the association of triglycerides and
prostate cancer severity, our data suggest that in Puerto
Rican prostate cancer patients with hypertriglyceridemia
the risk of more severe cancer is increased. Triglycerides
metabolism provides essential fatty acids [32]. It has
been suggested that in prostate cancer the lack of regu-
lation of LDL-receptor allows for the increased uptake
of essential fatty acids when LDL serum levels are ele-
vated. This provides a mechanism for Prostaglandin E2
(PGE2) synthesis, a known growth factor for cancer cells
[32, 33]. The relationship between triglycerides and the
severity could be explained by the contribution that high
levels of triglycerides make to the essential fatty acids
available for PGE2 production mechanism.
In addition, triglycerides levels include very low dens-
ity lipoproteins (VLDL), chylomicrons and remnant lipo-
proteins (RLP), produced after the hydrolysis of
chylomicrons and VLDL [34]. These RLPs bind to the
cells via the Apo E and ApoB/E receptors. In vitro stud-
ies have shown that 1 μg/mL of RLP induces the prolif-
eration of PC-3 prostate cancer cells, in a dose
dependent manner. This dose is comparable to levels of
10 ng/dL that have been detected in patients [35]. These
results should be further characterized in an in vivo
model.
Total Cholesterol, HDL and PCa severity
It is known that cholesterol plays an important role in
prostate cancer as a precursor of androgens, cell prolif-
eration mediator and inflammation [36]. Cholesterol is
also included within the lipid bimolecular layer of the
cell membrane, and this includes prostate cancer cells
[37]. We did not find statistically significant differences
in serum total cholesterol levels among the high and low
severity prostate cancer. These results diverge with pre-
vious studies [17, 28] which finds positive correlations
between lower cholesterol levels and lower risk of high-
grade cancer or studies associating cholesterol with
tumor growth in animal models [38–40]. It is important
to notice that among the many studies done to look for
associations between cholesterol levels and PCa or the
use of cholesterol reducing drugs, ie. statins and PCa
there are no standardized measurements for PCa grade
or severity. Some studies use only the GS, in two cat-
egories higher or lower than 7 [32] others use three [28]
and still others [17] as we do here, include the tumor
stage as part of the considerations to assess the severity
of the disease. Thus, the results are actually not fully
comparable among the studies.
The formation of lipid rafts in PCa cells have been
postulated to facilitate signaling in cancer cells that fos-
ter carcinogenic transformation throughout time. Ad-
mittedly, our cholesterol findings are limited by the lack
of longitudinal data regarding the patients’ cholesterol
levels, thus we cannot assess the effect of the range of
time that the patient had high or low cholesterol levels
and the PCa phenotype. In addition, the role of other
Table 3 Logistic regression models of factors associated to the PCa severity among a sample of male patients in Puerto Rico
Characteristic Unadjusted OR (95 % CI) p-value Adjusted OR (95 % CI)a p-value
Age at PCa diagnosis (years)
<60 1.0 1.0
≥60 2.34 (1.25–4.40) 0.012 2.59 (1.34–5.02) 0.005
BMI (Kg/m2)
<25.00 1.0 1.0
25–29.99 1.47 (0.62–3.46) 0.381 1.26 (0.51–3.10) 0.614
≥30.00 2.18 (0.88–5.40) 0.092 2.28 (0.88–5.89) 0.089
Triglycerides (mg/dL)
<150 1.0 1.0
≥150 2.11 (1.13–3.93) 0.019 1.78 (0.91–3.49) 0.093
HDL Cholesterol (mg/dL)
≥40 1.0 1.0
<40 1.90 (1.02–3.56) 0.044 1.73 (0.87–3.42) 0.117
aAdjusted by all variables in the model. No interaction in the model, p-value from the Likelihood-ratio test = 0.4899
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cholesterol susceptible pathways in carcinogenesis must
be addressed.
In our study group, a higher percentage of patients with
high HDL levels had low severity PCa. It has been sug-
gested that HDL plays a protective role in the pathophysi-
ology and cancer progression [41]. Low HDL effect could
be explained by reduced binding of PON-1(paraoxonase)
thus reducing PON-1free radical scavenging capacity [42].
Additionally, HDL may convey some protection from can-
cer severity by inhibiting the formation of lipid rafts which
have been associated to procarcinogenic cell signaling
through the activity of Caveolin-1(Cav-1) [43].
Conclusions
Undeniably, our study suffers from the limitations asso-
ciated to a small study group. It is not a longitudinal and
prospective study, thus the study design could not in-
clude an assessment of lifestyle habits that may act as
confounders.
Notwithstanding the limitations imposed by sample
size and lack of longitudinal data, this study sheds light
into the possible effects of lipids in the PCa phenotype
of an understudied population, with high overweight and
PCa mortality rates. Our data was not gathered island
wide but the treatment facility where we conducted our
study receives patients from all over the island, thus the
population, although small is not confined to the metro-
politan area of San Juan. Moreover, more than 95 % of
the patients had some type of medical insurance, there-
fore we are confident that the possible effect of lack of
access to medical care was probably not present in the
studied group. The potential clinical implication is that,
triglycerides and HDL levels may be related to PCa se-
verity and therefore relevant to patient management,
remarking that assessment of these lipid levels should be
part of the routine screening and diagnostic procedures.
We would like to conclude with the following: There is
a need for prospective, longitudinal and well-designed
studies, with adequate representation of ethnic and ra-
cial diversity to elucidate the role of HDL and LDL and




This study was approved by the Institutional Review
Board (IRB) of the University of Puerto Rico Medical
Sciences Campus (IRB approved protocol #8860211).
Study population
The studied population was chosen from patients under-
going treatment at a private medical facility in San Juan,
Puerto Rico which receives patients from all-over the
island and performed 516 radical prostatectomies (RP)
during the study period 2005–2012.
Inclusion criteria for the study were: Patients had to
be Puerto Rican, defined as being born in Puerto Rico
with parents and grandparents also from Puerto Rico,
aged 40–75 years old. Importantly, Radical prostatec-
tomy (RP) was the first treatment for the PCa. Patients
were excluded if they had been diagnosed previously
with other cancers or had viral infections at the time of
the first screening visit. Four hundred and eighty one
(481) patients’ records complied with these require-
ments. Out of the 481, we excluded 267 records that did
not have the lipid panel data. We also excluded patients
records (n = 15) that were under statin treatment for
cholesterol management. Ultimately 199 records were
included in the study.
Data collection procedures
The following clinical information was recorded from med-
ical charts: age, fasting serum lipid levels at the time of their
diagnosis, pre-radical prostatectomy PSA, height, weight,
and prostatectomy GS and Pathologic Stage from pathology
report. Lipid data accrued included triglycerides, choles-
terol, and lipoproteins (HDL and LDL). Lipid levels were
recorded from the patients’ first visit to the facility prior to
any intervention. Lipids were categorized following the US
National Institutes of Health - National Cholesterol Educa-
tion Program ATP III guidelines (Table 4) [44]. Height and
weight were used to calculate BMI according to Centers
for Disease Control formula (weight [kg]/height2 [m2]).
BMI categories were defined as underweight/normal
(≤24.9 kg/m2), overweight (25.0–29.9 kg/m2), and obese
(≥30.0 kg/m2).
Disease severity was defined using both the prostatec-
tomy GS and the American Joint Committee on Cancer
(AJCC) prostate cancer Pathologic Staging [45]. Low se-
verity was defined as GS ≤7 (3 + 4) and pathologic
stage ≤ pT2c. High severity was defined as GS ≤7 (3 + 4)
and pathologic stage ≥ pT3a or GS ≥7 (4 + 3) and patho-
logic stage > pT2c.
Statistical analysis
Univariate analysis was performed to characterize the
population (n = 199) according to demographic and clin-
ical characteristics. Contingency tables were generated
Table 4 Lipid levels categories following the US National
Institutes of Health - National Cholesterol Education Program
ATP III guidelines
Triglycerides Desirable: <150 mg/dL Non desirable: >150 mg/dL
Cholesterol Desirable: <200 mg/dL Non desirable: >200 mg/dL
HDL Low: <40 mg/dL High: >40 mg/dL
LDL Low: <160 mg/dL High: >160 mg/dL
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to assess the relationship of demographic and clinical
characteristics with prostate cancer severity using Pear-
son chi-square test. Unadjusted and adjusted logistic re-
gression models were fitted to estimate the odds ratios
(ORs) with 95 % confidence intervals (CI) to define these
relationships. Variables statistically associated with PCa
severity (p < 0.10) in the unadjusted logistic regression
models were included in the multivariate logistic regres-
sion model. Considering the sample size we used a level of
p ≤ 0.10 as a screening criterion for variable selection for
the multivariate logistic regression model, to which a level
of p ≤ 0.05was assigned. This statistical and epidemio-
logical decision was based on recommendations done by
Bendel and Afifi [46] and Mickey and Greenland [47] on
logistic regression. These authors show that use of a more
traditional level (such as 0.05) often falls to identify
variables that have clinical and scientific significance. All
analyses were performed using STATA 12.0 (College
Station, Texas, USA)
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